Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis

Jerry Fu,Twan Sia,Rachel Solecki,Shibani Mallik,Raisa Khuda,Madison Headen,Leeon Bacchus,Michelle Zheng,Tanvi Telukunta,Saad Shami,Stanley Liu,Sripad Sureshbabu,Kathleen Love,Alyssa Roby,Paige McDonald,Yuting Jiang,Dharaneswari Hari Narayanan,Evan Cunningham,Sara Matmatte,Puay Eng Tan,John Leung

DOI: https://doi.org/10.1016/j.jaip.2024.02.031

IF: 11.022

2024-02-29

The Journal of Allergy and Clinical Immunology In Practice

Abstract:There are currently no FDA-approved medications for eosinophilic gastritis and duodenitis. We present a novel case of a patient with eosinophilic gastritis and duodenitis who achieved histologic and symptomatic remission with upadacitinib, a Janus Kinase-1 (JAK1) inhibitor.

immunology,allergy